CO6811812A2 - Anticuerpo anti-b7-h3 - Google Patents

Anticuerpo anti-b7-h3

Info

Publication number
CO6811812A2
CO6811812A2 CO13275282A CO13275282A CO6811812A2 CO 6811812 A2 CO6811812 A2 CO 6811812A2 CO 13275282 A CO13275282 A CO 13275282A CO 13275282 A CO13275282 A CO 13275282A CO 6811812 A2 CO6811812 A2 CO 6811812A2
Authority
CO
Colombia
Application number
CO13275282A
Other languages
English (en)
Inventor
Shu Takahashi
Tatsuji Matsuoka
Kenji Murakami
Takeshi Takizawa
Kenji Hirotani
Atsushi Urano
Keisuke Fukuchi
Mitsuhiro Yazawa
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201161478878P priority Critical
Priority to JP2011097645 priority
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of CO6811812A2 publication Critical patent/CO6811812A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
CO13275282A 2011-04-25 2013-11-22 Anticuerpo anti-b7-h3 CO6811812A2 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201161478878P true 2011-04-25 2011-04-25
JP2011097645 2011-04-25

Publications (1)

Publication Number Publication Date
CO6811812A2 true CO6811812A2 (es) 2013-12-16

Family

ID=47072232

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13275282A CO6811812A2 (es) 2011-04-25 2013-11-22 Anticuerpo anti-b7-h3

Country Status (26)

Country Link
US (2) US9371395B2 (es)
EP (1) EP2703486B1 (es)
JP (2) JP5917498B2 (es)
KR (1) KR102030987B1 (es)
CN (1) CN103687945B (es)
AU (1) AU2012248470B2 (es)
CA (1) CA2834136C (es)
CO (1) CO6811812A2 (es)
DK (1) DK2703486T3 (es)
ES (1) ES2667568T3 (es)
HR (1) HRP20180640T1 (es)
HU (1) HUE038685T2 (es)
IL (1) IL229061A (es)
LT (1) LT2703486T (es)
MX (1) MX344773B (es)
NZ (1) NZ616809A (es)
PL (1) PL2703486T3 (es)
PT (1) PT2703486T (es)
RS (1) RS57279B1 (es)
RU (1) RU2668170C2 (es)
SG (1) SG194620A1 (es)
SI (1) SI2703486T1 (es)
TR (1) TR201808018T4 (es)
TW (1) TWI561531B (es)
WO (1) WO2012147713A1 (es)
ZA (1) ZA201307983B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI561531B (en) * 2011-04-25 2016-12-11 Daiichi Sankyo Co Ltd Anti b7-h3 antibody
WO2014160627A1 (en) 2013-03-25 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
EP3149040A1 (en) * 2014-05-29 2017-04-05 Spring Bioscience Corporation Anti-b7-h3 antibodies and diagnostic uses thereof
CA2961609A1 (en) 2014-09-17 2016-03-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 antibodies (b7h3)
BR112018005777A2 (pt) 2015-09-24 2018-10-09 Daiichi Sankyo Company, Limited anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produzir um anticorpo de interesse ou um fragmento do mesmo composição farmacêutica, e, uso de pelo menos um anticorpo
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
CN109843927A (zh) * 2017-03-06 2019-06-04 江苏恒瑞医药股份有限公司 抗b7-h3抗体、其抗原结合片段及其医药用途
TW201837056A (zh) * 2017-03-31 2018-10-16 大陸商江蘇恆瑞醫藥股份有限公司 B7-h3抗體、其抗原結合片段及其醫藥用途
WO2019024911A1 (zh) * 2017-08-04 2019-02-07 江苏恒瑞医药股份有限公司 B7h3抗体-药物偶联物及其医药用途
WO2019225787A1 (ko) * 2018-05-24 2019-11-28 에이비엘바이오 주식회사 항-b7-h3 항체 및 그 용도
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
WO2020047462A2 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2020047333A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
WO2020047299A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CN110950953A (zh) * 2018-09-26 2020-04-03 福建医科大学 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
CN109851673A (zh) * 2019-01-22 2019-06-07 苏州旭光科星生物技术有限公司 一种抗人b7-h3单克隆抗体的制备方法及其免疫组化检测方法及其应用及其试剂盒

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JP3540315B2 (ja) 1991-09-23 2004-07-07 ケンブリッジ アンティボディー テクノロジー リミティド キメラ抗体の製造−組合せアプローチ
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AT463573T (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
JPH09506508A (ja) 1993-12-03 1997-06-30 メディカル リサーチ カウンシル 組換え結合タンパク質およびペプチド
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
JP4334141B2 (ja) * 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
WO2002010187A1 (en) * 2000-07-27 2002-02-07 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
AU2001294198C1 (en) 2000-10-06 2019-04-04 Kyowa Kirin Co., Ltd. Cells producing antibody compositions
CA2427858A1 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
HU230378B1 (hu) 2001-11-01 2016-03-29 Uab Research Foundation Anti-DR5 ellenanyagok és anti-DR4 ellenanyagok és más terápiás ágensek kombinációi
AU2004203727C1 (en) 2003-01-07 2008-08-21 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
US20050002935A1 (en) * 2003-04-17 2005-01-06 Vincent Ling Use of B7-H3 as an immunoregulatory agent
JP5130044B2 (ja) * 2004-08-03 2013-01-30 イナート・ファルマInnate Pharma 4ig−b7−h3およびその対応するnk細胞受容体を標的化する治療および診断方法ならびに組成物
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CN101104639A (zh) * 2006-07-10 2008-01-16 苏州大学 抗人b7-h3单克隆抗体的制备及其应用
EP2094307A4 (en) 2006-11-08 2015-08-26 Macrogenics West Inc Tes7 and antibodies that bind thereto
EP2121008A4 (en) 2007-03-22 2010-03-31 Sloan Kettering Inst Cancer Uses of monoclonal antibody 8h9
TWI561531B (en) * 2011-04-25 2016-12-11 Daiichi Sankyo Co Ltd Anti b7-h3 antibody

Also Published As

Publication number Publication date
WO2012147713A1 (ja) 2012-11-01
NZ616809A (en) 2015-08-28
PT2703486T (pt) 2018-05-18
RU2013152164A (ru) 2015-05-27
SI2703486T1 (en) 2018-05-31
US20160368990A1 (en) 2016-12-22
JP2016165294A (ja) 2016-09-15
AU2012248470B2 (en) 2016-10-27
IL229061D0 (en) 2013-12-31
US20130078234A1 (en) 2013-03-28
DK2703486T3 (en) 2018-05-28
TR201808018T4 (tr) 2018-06-21
IL229061A (en) 2019-02-28
HUE038685T2 (hu) 2018-11-28
ES2667568T3 (es) 2018-05-11
CA2834136A1 (en) 2012-11-01
KR102030987B1 (ko) 2019-11-11
TW201249869A (en) 2012-12-16
MX2013012285A (es) 2013-11-21
HRP20180640T1 (hr) 2018-06-01
JP6224759B2 (ja) 2017-11-01
CN103687945A (zh) 2014-03-26
CN103687945B (zh) 2016-10-12
EP2703486A1 (en) 2014-03-05
LT2703486T (lt) 2018-05-25
EP2703486B1 (en) 2018-03-07
MX344773B (es) 2017-01-06
CA2834136C (en) 2018-04-17
TWI561531B (en) 2016-12-11
AU2012248470A1 (en) 2013-11-21
SG194620A1 (en) 2013-12-30
KR20140033018A (ko) 2014-03-17
RU2668170C2 (ru) 2018-09-26
PL2703486T3 (pl) 2018-07-31
EP2703486A4 (en) 2015-02-25
RS57279B1 (sr) 2018-08-31
JPWO2012147713A1 (ja) 2014-07-28
JP5917498B2 (ja) 2016-05-18
US9371395B2 (en) 2016-06-21
ZA201307983B (en) 2016-01-27

Similar Documents

Publication Publication Date Title
NO2019006I1 (no) Tisagenlekleucel
NO2019020I1 (no) lanadelumab
NO2019034I1 (no) lorlatinib
CO7010838A2 (es) Compuestos de imidazopirrolidinona
CO6821899A2 (es) Gesto de margen
CO6900145A2 (es) Compuesto de ciclopropanoamina
CO6920260A2 (es) Ambiente de aplicación múltiple
CO6852047A2 (es) Ensamble desgastable
NO2019038I1 (no) Risankizumab
CO6811828A2 (es) Nebulizador
CR20130231A (es) Compuestos antivirales
CO6801645A2 (es) Nuevos inmunoconjugados
CO6900146A2 (es) Imidazopiridazinas sustituidas con amino
NO2018039I1 (no) Rukaparibkamsylat
CO6862160A2 (es) Indazoles
SMT201700065B (it) Derivato piridonico
CO6890099A2 (es) Nuevos derivados dihidroquinolina-2-ona
NO20110476A1 (no) UAV-sett
CO6980657A2 (es) Triazolopiridinas sustituidas
NO2010019I2 (no) 6-per-deoksy-6-per-(2-karboksetyl)tio-y-cyklodextrin
NO2019022I1 (no) Natriumzirkoniumsyklosilikat
NO2017034I1 (no) Idarucizumab
CO6801652A2 (es) Genes sintéticos
CO7020871A2 (es) Anticuerpos anti-il-36r
CR20130111A (es) Triazina-oxidiazoles

Legal Events

Date Code Title Description
FG Application granted